Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

More information needed

November 10, 2008

Analysis of:Pfizer’s TOVIAZ™ (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder | www.pipelinereview.com

Not data comparing new drug (Toviaz) to old (Detrol) with respect to efficacy. Does Toviaz have any benefits over existing alternatives, or is it just an attempt to market a more expensive alternative with a reset patent time-clock?

Overuse, under-focus

November 6, 2008

Analysis of:Taking Statins To The Next Level | www.forbes.com

Little additional sales will be gained by growth in the statin market.

skepticism

October 22, 2008

Analysis of:WellPoint, X Prize launch $10M health care contest | news.yahoo.com

The HC system is a 2 trillion ton gorilla -- proving that an idea can move it, doesn't mean that it will. The incentives to improve efficiency in healthcare already greatly surpass 10 million dollars, though maybe not for the right people.

Medical treatment -- the unacknowledged Tragedy of the Commons

August 11, 2008

Analysis of:UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com

Insured patients believe they should have access to any and all treatments regardless of cost.As limited resources must be shared, some will be unhappy with the allowances.These drugs could command as much as 0.3% of the NHS budget.

Xenophobia and Valid Fears: Chinese comestibles and US Health

May 21, 2008

Analysis of:China Muscles In On The Generics Industry | www.pharmalot.com

Until Chinese regulations and enforcement catch up with Western consumer standards, the market for Chinese pharmaceuticals will be greatly diminished by its reputation.

Licensure and Training

May 19, 2008

Analysis of:Renal Failure Linked to Cosmetic Soft-Tissue Filler Injections | www.medscape.com

Inexperienced and inadequately trained healthcare practitioners are certain to have higher error rates. This applies to pharmacy-based on-site clinics run by NPs that are springing up nationwide. How are these clinics regulated? Who is responsible if things go wrong?

Cover all the uninsured without spending a penny

November 8, 2007

Analysis of:Universal Health Coverage Attracts New Support | www.washingtonpost.com

Expanding healthcare to the uninsured via the vehicle of private insurance will only increase costs without increases in efficiency. Candidates are beholden to special interests and therefore propose bandaid approaches to health insurance reform without getting at the root of the problem.

Why inject?

October 8, 2007

Analysis of:Critical Therapeutics Initiates Phase II Clinical Trial for Zileuton Injection | www.pipelinereview.com

The patients are not experiencing acute exacerbations of their asthma. Since Zileuton is already avaialble in an oral formulation, why would patients who aren't having acute concerns want an injection? Why was the IV not compared with the oral? If it is more effective, it may be worth using, but if equivalent, there may be no benefit.

Quality of life versus quality of care

October 4, 2007

Analysis of:Burden of diabetes care rivals disease complications | www.reuters.com

When patients elect to follow any physician advice, they are in effect demonstrating that they have weighed the costs of that advice (time, money, lifestyle modifications, etc) with the expected benefits. All too often, however, patients do not understand or grossly underestimate the costs of not taking the advice. This article highlights a simple point: physicians are, at bottom, life consultants. They can provide advice, based usually upon research or concensus opinion, but must also educate patients on the pros and cons of each approach. Patients must also be aided in recognizing the difference between and consequences of active as opposed to passive decisions.

Marvelous capitalist move

October 3, 2007

Analysis of:Barrier Therapeutics Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Hyphanox(TM) for Onychomycosis | www.pipelinereview.com

More money, less innovation

Page : 11 to 10 of 10

Subscribe to Updates

By RSS